Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00590941 · ClinicalTrials.gov registry record · NA
Genetic Determinations for Side Effects and Response Rate for Patients Receiving Chemotherapy With Diffuse Large Cell Lymphoma
A NA study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- NA
- Development phase
- 52
- Enrollment target
NCT00590941 is a NA study that has completed, run by Washington University School of Medicine. The registered enrollment target is 52 participants.
The verdict
NCT00590941, a NA study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 52 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether people have genes that make them more likely to respond to chemotherapy and/or have side effects from chemotherapy for diffuse large cell lymphoma.
Interventions
- PROCEDURE Blood draw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2005-02 |
| Est. Completion | 2011-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00590941
The ClinicalTrials.gov registry entry for NCT00590941 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Blood draw is the first listed.
NCT00590941 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00590941 about?
NCT00590941 is a clinical study titled "Genetic Determinations for Side Effects and Response Rate for Patients Receiving Chemotherapy With Diffuse Large Cell Lymphoma". The purpose of this study is to determine whether people have genes that make them more likely to respond to chemotherapy and/or have side effects from chemotherapy for diffuse large cell lymphoma.
What is the current status of trial NCT00590941?
This trial is currently completed. It is a NA study. The enrollment target is 52 participants. The study started on 2005-02. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00590941?
The interventions under investigation include: Blood draw (PROCEDURE).
Who is sponsoring clinical trial NCT00590941?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.